GRAIL collaborates with AZN to make companion diagnostic tests for early-stage cancer
seekingalpha.com
finance
2022-06-02 13:59:02

vitanovski/iStock via Getty Images Illumina (NASDAQ:ILMN) unit GRAIL on Thursday announced a collaboration with AstraZeneca (AZN) to make and sell companion diagnostic assays for use with AZN's therapies. GRAIL, which focuses on technologies for early detection of cancer, said the collaboration will initially focus on developing companion diagnostic tests to identify patients with high-risk, early-stage cancers. GRAIL and AZN are also planning to use GRAIL's technology to enable recruitment of patients with early-stage cancer for Astra's clinical studies.
